These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17455324)

  • 1. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics.
    Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D
    J Pharm Sci; 2007 May; 96(5):1282-301. PubMed ID: 17455324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics.
    Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D
    J Pharm Sci; 2007 May; 96(5):1302-19. PubMed ID: 17455364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactose composite carriers for respiratory delivery.
    Young PM; Kwok P; Adi H; Chan HK; Traini D
    Pharm Res; 2009 Apr; 26(4):802-10. PubMed ID: 19015956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
    Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
    J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.
    Sethuraman VV; Hickey AJ
    AAPS PharmSciTech; 2002; 3(4):E28. PubMed ID: 12916922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations.
    Adi H; Traini D; Chan HK; Young PM
    J Pharm Sci; 2008 Jul; 97(7):2780-8. PubMed ID: 17894369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance.
    Young PM; Chan HK; Chiou H; Edge S; Tee TH; Traini D
    J Pharm Sci; 2007 May; 96(5):1331-41. PubMed ID: 17455362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of dry powder inhalers.
    Chougule MB; Padhi BK; Jinturkar KA; Misra A
    Recent Pat Drug Deliv Formul; 2007; 1(1):11-21. PubMed ID: 19075871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
    Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
    Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PulmoSphere™ platform for pulmonary drug delivery.
    Weers J; Tarara T
    Ther Deliv; 2014 Mar; 5(3):277-95. PubMed ID: 24592954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces.
    Zhou QT; Morton DA
    Adv Drug Deliv Rev; 2012 Mar; 64(3):275-84. PubMed ID: 21782866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of particle properties in pharmaceutical powder inhalation formulations.
    Chew NY; Chan HK
    J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.
    Jones MD; Buckton G
    Int J Pharm; 2016 Jul; 509(1-2):419-430. PubMed ID: 27265314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate.
    Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
    J Pharm Sci; 2010 Aug; 99(8):3398-414. PubMed ID: 20198688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.